FDA Pumps Brakes On Eli Lilly Alzheimer's Drug Approval
The U.S. Food and Drug Administration is delaying an approval decision on Eli Lilly and Co.'s Alzheimer's drug donanemab, the company said Friday, throwing a wrench in what was expected to...To view the full article, register now.
Already a subscriber? Click here to view full article